



(51) International Patent Classification:

A61K 47/68 (2017.01) C07D 491/22 (2006.01)

A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2023/078842

(22) International Filing Date:

06 November 2023 (06.11.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/422,517 04 November 2022 (04.11.2022) US

(71) Applicant: ALX ONCOLOGY INC. [US/US]; 323 Allerton Ave, South San Francisco, California 94080 (US).

(72) Inventors: PONS, Jaume; 323 Allerton Ave, South San Francisco, California 94080 (US). VRLJIC, Marija; 461 W. 25th Avenue, San Mateo, California 994403 (US). STROP, Peter; 2701 E. Manzanita Avenue, Tucson, Arizona 85718 (US). WONG, Janica Cheuk-Ying; 323 Allerton Ave, South San Francisco, California 94080 (US). DAINO-LAIZURE, Hanako; 323 Allerton Ave, South San Francisco, California 94080 (US).

(74) Agent: KAVANAUGH, Theresa C.; Goodwin Procter LLP, 100 Northern Avenue, IP DOCKETING DEPT/7TH FL, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: EXATECAN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES THEREOF

FIG. 1A



(57) Abstract: Disclosed herein, in part, are novel exatecan derivatives with novel chemical linkers that include cathepsin B cleavable moieties and conjugated to targeting antibodies. In a preferred embodiment the antibody is an anti-TROP2, an anti-EGFR or an anti-HER2 antibody.